Day: March 28, 2024

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) reports that Kulwant Malhi has resigned as President and Director of the Company. Mr. Malhi is the CEO of privately held BullRun Capital Inc. and founded Cannabix Technologies Inc. in 2014 and was integral in Cannabix Technologies Inc. becoming a public company on the Canadian Securities Exchange and subsequent financing rounds. Mr. Malhi states, “I am pleased to be leaving my Executive role at Cannabix and focusing on our other BullRun Capital early-stage incubations. I believe Cannabix is at a turning point towards proving its technology on a commercial foundation and I wish the Company well in future developments.” The Company thanks Mr. Malhi for his contributions and wishes him...

SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) — On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and normalized profit for the year that excluding provisions of impairment losses on related assets was RMB2,709 million. The results announcement shows that in 2023, the Company has affected by the implementation of the National Volume Based Procurement (the “National VBP”) of its three marketed original products (sales of these three products recorded a decrease of RMB1,708.7 million, and the sales of them for the second...

Funding from new and existing investors extends anticipated cash runway into H2 2026 SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share. Erasca anticipates the gross proceeds from the private placement will be approximately $45 million, before deducting placement agent fees and other offering expenses. The private placement is expected to close on or about April 2, 2024, subject to customary...

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be...